OmniAb - Q3 2024

Executive Summary

• Q3 2024 revenue was $4.2M, down year-over-year and sequentially (Q3 2023: $5.5M; Q2 2024: $7.6M), driven by timing of milestones and lower ion channel service revenue; management reiterated that milestone revenue remains weighted to 2H with most shifting into Q4.
• Net loss was $16.4M ($0.16 per share), roughly flat vs. prior year ($15.7M, $0.16) and wider vs. Q2 ($13.6M, $0.13), as revenue softness outweighed lower R&D and G&A expenses.
• Liquidity improved via ATM issuance: $8.5M raised in Q3 and $2.9M post-quarter, with year-end cash guided to $50–$60M; management expects 2025 cash use lower than 2024 (excluding ATM proceeds).
• Operational momentum: active partners rose to 86, active programs to 352, and clinical-stage/approved programs to 33; management highlighted growing interest in multispecifics, single-domain antibodies (OmnidAb), and the OmniHub AI/bioinformatics platform launch in December.

What Went Well and What Went Wrong

What Went Well

• Partner and program growth: 86 active partners (+3 QoQ) and 352 active programs; 33 programs in clinical development/approved, with multiple new clinical entries expected by year-end, supporting future milestone potential >$550M across post-discovery assets.
• Technology/platform progress: OmniHub announced for December launch to integrate ML/AI with bioinformatics; management sees it enhancing discovery workflows and partner interactions (part of standard offering).
• Partner pipeline updates: notable advances at Immunovant (IMVT-1402 INDs cleared and registrational starts targeted), Genmab (acasunlimab Phase 3 expected start), Teva (TEV-53408 Phase 1 data), and CStone (MHRA approval of sugemalimab; 4-year survival data).

Quotes:

• “We are pleased to report another successful quarter…a highly scalable model with cutting-edge technologies…” – CEO Matt Foehr.
• “We ended Q3 with 86 active partners…looking to finish the year strong in our business development…” – CEO Matt Foehr.
• “We continue to anticipate total operating expenses in 2024 to be slightly less than total operating expenses in 2023.” – CFO Kurt Gustafson.

What Went Wrong

• Revenue softness: Q3 revenue fell to $4.2M from $7.6M in Q2 and $5.5M in Q3 2023, primarily due to milestone timing and lower ion channel service revenue; milestones expected in Q4 but cash collection timing may slip into Q1 2025.
• Net loss widened sequentially: Q3 net loss ($16.4M) larger than Q2 ($13.6M) as revenue declined; EPS held at ($0.16) YoY despite lower OpEx, reflecting operating leverage still ahead of revenue scale.
• Macro headwinds: management cited biopharma funding pressures and big pharma pipeline reprioritization creating volatility; ATM equity issuance was used as prudential “cushion”.

Transcript

Operator (participant)

Good afternoon and welcome to OmniAb Inc. Q3 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the call over to Kurt Gustafson, OmniAb Inc. Chief Financial Officer. You may begin. Thank you.

Kurt Gustafson (CFO)

Thank you, Operator, and good afternoon to everyone. This is Kurt Gustafson, OmniAb's CFO. Thank you all for joining our Q3 2024 financial results conference call. There are slides to accompany today's remarks, and they're available in the Investor section of our website at www.omniab.com. Before we begin, I'd like to remind listeners that comments made during this call by management will include forward-looking statements within the meaning of federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from any anticipated results. These forward-looking statements are qualified by our cautionary statements contained in today's press release and our SEC filings. Importantly, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast today, November 12, 2024.

Except as required by law, OmniAb undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Joining me on the call today is Matt Foehr, OmniAb's President and CEO, and during today's call, Matt and I will provide highlights in the company's operations, partner and technology updates, and our recent financial results. At the conclusion of the prepared remarks, we'll open the call to questions, and with that, let me turn the call over to Matt.

Matt Foehr (President and CEO)

Thanks, Kurt. Good afternoon, everyone, and thanks for joining us today on our Q3 call. We've continued to deliver robust performance across our key metrics and are building momentum in the business. With strong execution and a leverageable business model, we're well situated to navigate a variety of industry cycles with a business that's now positioned for success. Our diversified base of partners and programs continues to grow and continued to grow during the Q3, despite a backdrop of a somewhat challenging macro environment presenting headwinds to some areas of the pharma, discovery, tools, and technology space this year. As our partners' clinical stage programs advance, we're also gaining better insights into timing around key inflection points for preclinical and later-stage programs. These post-discovery programs represent just a subset of our growing portfolio and have over $550 million in potential milestones to OmniAb.

We're committed to driving innovation, to further differentiate our technologies, and to bolster our pipeline. And we're excited both about the potential opportunities ahead and our important place within the global pharmaceutical industry. I'll now quickly review some of our business metrics starting here on slide number five. As shown here on the chart on the left-hand side, we ended Q3 with 86 active partners. We signed three new platform license agreements during the quarter. That included new agreements with 92Bio, Memorial Sloan Kettering Cancer Center, and Queen Mary University of London. Strong partnerships like these are fundamental to our success, and we remain committed to expanding our partnership base while helping partners realize their research and discovery goals. Also, I'll mention here that we recently expanded our ion channel screening relationship with Syngenta, which began last year. And we also recently entered into a new license with Orion Corporation.

We're looking to finish the year strong in our business development and licensing efforts, and this year could potentially be our best year ever in that regard. Our growth in partner count reflects the industry's interest in our technology and our dedication to both innovation and collaboration. By fostering these relationships, we believe we're creating new opportunities for mutual success, and an added benefit is that our deep relationships with our partners help inform the intelligent expansion of our platform. Our partnerships provide a valuable vantage point on current industry trends and future opportunities, and also keep OmniAb on the leading edge of in-demand technologies. The number of active programs underway by our partners remains robust, and year-to-date new program additions have been strong. As shown here on slide number six, as of September 30, active programs increased to 352 net of attrition.

As you'll see on this slide, we're now providing more detail on our active programs. We're displaying both attrition and additions on the right side of the slide in the call-out bar graph, shown here on the screen in the orange and the green bars. As of the end of the Q3, we had 12 terminations and 39 active program additions. We often say that terminations or attrition are a natural part of drug development, and as we've noted this year and as reported more broadly in the industry, certain pharma companies continue to realign and reprioritize their therapeutic programs and pipelines. Having said that, our net growth and number of active programs continues to validate our technology platform.

We've generated growth net of attrition over multiple years now in a variety of macroeconomic and industry cycles, which I think demonstrates our ability to continuously evolve and enhance our technologies and expand our reach. As I mentioned on the previous slide, our deep relationships with our partners position us really well as we focus our innovation efforts. Now on slide 7, as of September 30, our partners had 33 active clinical programs and approved products. During the quarter, Genmab's GEN1057, an investigational proprietary bispecific antibody, and Merck KGaA's M5542, which is a fusion protein, both advanced into phase I clinical trials. Genmab's GEN1053 came out of our clinical program count shown on this slide and shifted back to the preclinical stage. According to Genmab's public disclosures, they're discontinuing a phase II clinical trial in solid tumors for GEN1053, while preclinical activities in other indications remain active and ongoing.

As of the end of Q3, three new OmniAb-derived programs have entered human clinical trials in 2024. Based on discussions with our partners, we continue to expect that we'll see one to three additional entries in the clinical development for novel OmniAb-derived antibodies by year-end. Our post-discovery assets, which include preclinical and later-stage programs, have the potential to drive near-term and mid-term value generation. Now on slide number 8, you see the increased count in these assets. Over the past two years, we've maintained impressive growth with a 40% increase in the number of these programs, reaching a total of 53 by the end of Q3. As I mentioned earlier, the programs depicted here have over $550 million in contracted potential milestones to OmniAb. The successful progression of our partners' programs showcases our collaborative efforts and our shared vision, along with the value that our technologies can create.

Here on slide number nine, I'll just briefly touch on some select partner updates. Immunovant has made significant progress on development of IMVT-1402. Late last week, they announced IND clearance for rheumatoid arthritis, where they stated that IMVT-1402 has a potential best-in-class profile for difficult-to-treat RA. They also announced that five INDs have been cleared by the FDA in a range of therapeutic applications and that they're on track to initiate potentially registrational trials of IMVT-1402 in four to five indications by the end of Q1 of next year. They also reported positive results from the phase IIa trial of batoclimab in Graves' disease. In addition, they announced alignment with the FDA and IND clearance and an expectation to initiate a pivotal trial of IMVT-1402 in Graves' disease by the end of this year.

Genmab highlighted both acisunlimab and GEN1057 on their earnings call last week as well. They described their priority in continuing to build a world-class differentiated pipeline and highlighted the phase III study of acisunlimab in second-line non-small cell lung cancer and that it's on track to start this year. They also highlighted the recently initiated phase II trial of GEN1057 in malignant solid tumors. At the ESMO conference, BioCity presented interim phase I clinical trial results on the safety and efficacy of their first-in-class antibody-drug conjugate, BC3195, which targets CDH3. They reported that 3195 demonstrated impressive anti-tumor activity in patients with advanced non-small cell lung cancer and that the drug is in concurrent dose optimization and dose expansion studies in China. Teva recently disclosed phase I data for TEV-53408, which is an anti-IL-15 discovered in our OmniRat technology.

Teva indicated that 408 is showing a potential best-in-class profile, noting high affinity for IL-15, prolonged suppression of free IL-15, and a potential for low dosing frequency. It was well tolerated in a first-in-human study, and a proof-of-concept study in celiac disease is in progress. Last week, Teva also disclosed the initiation of a clinical study in vitiligo, which is an autoimmune disease with significant unmet medical need. On my last slide here, slide number 10, I'd like to highlight a couple of upcoming scientific conferences by our team. We continue to increase the visibility of our differentiated technology platforms at relevant scientific conferences by showcasing innovations that we think create value for our partners.

Next month, we'll be at the Antibody Engineering and Therapeutics Conference down in San Diego, where our team will present workflows for discovering developable binders with broad epitope coverage and affinities that serve as building blocks for multi-specifics, which is an area of significant and growing interest in the industry. In another presentation, we'll discuss the design and implementation of OmniHub, which is a new platform we're launching for bioinformatics tools that also enhances antibody discovery workflows by integrating machine learning and AI tools with our deep bioinformatics capabilities. When we kicked off the year, we mentioned that we'd be rolling out some partner experience enhancements, and OmniHub is one example of this. And with that, let me now turn the call back to Kurt for a discussion of our Q3 financials. Kurt?

Kurt Gustafson (CFO)

Thanks, Matt. The income statement on slide 12 summarizes our financial performance in the Q3 of 2024. Total revenue for the quarter was $4.2 million, and this compares with $5.5 million in the prior year quarter. The decrease is primarily due to lower milestone revenue and lower ion channel service revenue. We had previously guided that our revenue would be weighted towards the second half of the year. That guidance was based on statements and information from our partners, and we still believe this to be true. However, it looks like most of those milestones will hit in the Q4. Our R&D expense for the Q3 was $13.3 million compared to $13.9 million in the prior year quarter, with the decrease primarily due to lower stock-based compensation expense.

Our G&A expense was $7.1 million for the quarter compared to $8.5 million a year ago, with the decrease primarily due to lower legal costs and lower stock-based compensation. Our operating expenses are in line with our expectation, and we continue to anticipate total operating expenses in 2024 to be slightly less than total operating expenses in 2023. The net loss for the Q3 of 2024 was $16.4 million, or 16 cents per share, versus a net loss of $15.7 million, or 16 cents per share, in the prior year period. Turning to slide 13, you'll see our balance sheet as of September 30, 2024. We ended the Q3 with $59.4 million in cash, which includes $8.5 million of capital raised through our at-the-market security offering.

We raised an additional $2.9 million under the ATM program subsequent to the end of the quarter, which will be reflected in our Q4 financial statements. As the year progressed, we continued to observe pressure on the biopharmaceutical industry, which has led to restructurings and pipeline reprioritizations. This can drive additional volatility in our business, and given these dynamics, we believed it was prudent to add some cushion to our balance sheet through the issuance of stock off our ATM program. These new funds strengthen our cash position, enhance our financial and strategic flexibility, and better prepare us for potential risks driven by macroeconomic and varying industry conditions and cycles. At this point, we believe the company is well capitalized, and we enter 2025 in a better financial position.

With regards to cash guidance, we expect to end 2024 with a cash balance in the range of $50-$60 million, which includes the proceeds from the recent ATM issuance. We anticipate that certain development milestones will be achieved in the Q4. However, due to the payment terms of our agreements that typically range from 30 to 60 days, the actual cash collection for some of these milestones may not occur until the first quarter of next year, which is what drives the broad range. With regards to cash guidance for 2025, given the current expected progression of our existing partnered pipeline, we expect that cash use in 2025 will be lower than in 2024, excluding the recent ATM program proceeds. And with that, I'd like to open up the call for questions. Operator?

Operator (participant)

Thank you. Ladies and gentlemen, we will now begin the question and answer session. Should you have a question, please press star followed by one on your touch-tone phone. You will hear a prompt that your hand has been raised. Should you decline from the polling process, please press star followed by two. If you are using speakerphone, please lift the handset before pressing any keys. Your first question comes from Puneet Souda with Leerink Partners. Please go ahead.

Hi, everyone. We have Michael on for Puneet today. Congrats on the quarter. I was wondering, just given the large step-up in the number of active programs this quarter, I was wondering if you could disentangle how much is from maybe a macro covering the biopharma space versus something that you as a company are doing, maybe gaining share or expanding in certain geographies?

Matt Foehr (President and CEO)

Yeah, Michael, thanks for the question. This is Matt. Yeah, I'll call out one detail here that probably wasn't lost on you, but we've provided a little more detail on our active program count. After kind of discussion with internal team and external stakeholders thought it would be useful, traditionally, we just reported numbers net of attrition, but now we're providing a little more detail on additions and attrition. And growth in program counts has been strong this year, and it continues to be strong. I think it's a testament to the new technologies that we've launched, our OmnidAb technology, which is really the first and only transgenic chicken that produces single-domain antibodies, which is a novel class of antibodies found naturally in camelids that is an area of growing interest in the industry for a variety of scientific reasons. We're getting a lot of interest in that.

That's driving a lot of new starts. And then I'll say the validation of the platform is as well. We balance that with the backdrop of the industry and some of the things we mentioned in the intro around big pharma companies realigning portfolios and pipelines and things like that. But program growth has been strong and continues to be strong.

Okay, great. And then I had a quick question about the OmniHub. I was curious if that's another add-on as part of a standard license or if that's going to be an additional revenue stream software-wise?

Yeah, yeah, thanks. It's another tool that we use in collaborating with our partners, right? So we're going to do a full launch of that at the AETC conference in December down in San Diego, and it's really meant as a way to facilitate and streamline and accelerate discovery interactions with our partners. As we've expanded our platform, we have the benefit of a core technology of our transgenic animals that produce really strong antibody responses that creates opportunities for us to leverage machine learning and AI and big data analysis in ways that others, frankly, can't, and OmniHub is a way in which we can interact with our partners to kind of facilitate their efforts downstream. So it's part of our standard offering.

We don't see it necessarily being a single business line item, but it's one of the ways that we continue to innovate and continue to remain on the cutting edge to meet our partners' needs, not only now, but in the future.

Great. Thank you very much.

Operator (participant)

Your next question comes from Matt Hewitt with Craig-Hallum. Please go ahead.

Hello, this is Tyler from the call for Matt Hewitt. We've heard some rumblings that while biotech is up this year compared to last, the amount raised has declined from earlier in the year until last quarter, and as a result, some companies are being a little more cautious with their investments. Are you hearing or seeing anything like that?

Kurt Gustafson (CFO)

Yeah, I think we sort of mentioned some of these macro and industry forces that we're observing. I think we're seeing the same things that you're talking about and seeing. And there certainly is pressure that's been created on the industry, and that we talked a little bit about that has created some of the volatility in our business. And so we maybe have a little bit more cautious outlook as we look ahead. All that being said, I think if you take a look at the key metrics that we have heavily focused on in terms of signing up new deals, partners continuing to see the value of our technology and starting new programs, moving things, progressing through the clinic, we're seeing progress on all of our key metrics.

So I don't discount the fact that there are some challenging industry things going on, but our business continues to perform well. I don't know, Matt, anything to add on?

Matt Foehr (President and CEO)

Not really. I'd say the only thing I'd add is we talked about how some of the larger pharmas have gone through what they call "portfolio shaping initiatives," those kinds of things, but that's balanced with we have a lot of discussions with those in the industry, and one of the things we also hear is that at times that they are focusing their work, they also look to the best platforms and the most validated technologies to help them meet their discovery needs, and that also can attract them to us, so yeah, a lot going on in the industry, but we feel good about our position.

Awesome. Thank you. And I do realize that it's early, but how should we be thinking about the range of new clinical entries by your partners next year?

Yeah, thanks. Great question. As we look into next year, and as we said, we expect one to three additional clinical entries before the end of this year, right? So just in the next six weeks or so, based on our discussions with partners. And as you look at our post-discovery assets, right now we have 20 assets in preclinical. We have a pretty high bar for what we consider to be preclinical assets. So those programs are candidates to move into the clinic in 2025. I expect as we get into next year, we'll talk about that in more detail. What we often find is that the J.P. Morgan conference at the beginning of January is often a time when many of our partners start talking more publicly about new programs, about new trials, about new indications, and their intentions for the year.

And so that's often a good time around that time or post that time for us to start talking in a little more specifics about some of the programs and the count that we expect. But we feel good about the growth in the portfolio and the matriculation of the programs through the various phases.

Thank you for the color.

Operator (participant)

Next question comes from Stephen Willey with Stifel. Please go ahead.

Stephen Willey (Analyst)

Yeah, good afternoon. Thanks for taking the question. So I guess you're talking about how growth and program counts remain strong. You mentioned that multi-specifics are an area of considerable growth for the industry. Do you know what proportion of new program starts you're seeing that are multi-specific in nature? Do you have that level of insight? And then do you also have any insight into the types of targets that partners are pursuing via these new program starts? I guess I'm just wondering if you have the ability to assess kind of where each annual cohort of new program starts kind of falls on the risk spectrum.

Matt Foehr (President and CEO)

Yeah, yeah, thanks, Steve. Great question, and the answer there is it's a range, right? But as our platform has become more widely used and more validated, the number of new modalities and approaches that partners are looking to employ downstream, leveraging our technology for discovering antibodies, continues to grow, and if you look even at our visible clinical programs, a growing number of those are bispecifics, right? Multispecifics are absolutely the next wave. And we've seen an increase in multispecifics this year and interest there, and I think our OmniDab technology is also driving that as well. We're also seeing more diversification in therapy areas and areas of interest. OmniDab opens up a lot more possibilities in neuroscience as well as in oncology, where we already have a pretty broad presence. So I'll just answer it generally and say it's absolutely increasing the interest in multispecifics.

And we're pleased that partners come to us because they realize we've got technologies that are designed to meet the needs there. That's something we've been talking with them about for a long time. So they know that we're there and our technologies are designed to help meet that need.

Stephen Willey (Analyst)

Okay, that's helpful. And then I think you may have given this information at some point last year, but do you have any update as to what the blended royalty rate of the post-discovery program portfolio looks like at this point? And then is there anything that you can say about how the IMVT-1402 asset, I guess, compares to that blended royalty rate? I know that that's an asset that is getting a lot of investor attention right now. Thanks.

Kurt Gustafson (CFO)

Yeah, Steve, I don't have an update for you on that blended royalty rate. We gave that number back in September, November or so of last year. But what I'll say is that that rate that we provided was based on the number of active programs that we had at the time, which was about 300. We obviously have grown the number of active programs, but it's kind of hard to move the needle on that number a whole lot. So while I don't have an update to that number, I would imagine it's not that much different than the number that we provided back in November. In terms of Immunovant programs, so just as a reminder, the way that that contract works is HanAll was the original party that we had a contract with.

So the way it works is Immunovant will pay HanAll, and we get a portion of whatever HanAll gets. And so it's a little bit of a different structure than kind of a straight license for us. But in terms of the royalty rate, our standard sort of saying is that the royalty rate that we get is in the low to mid-single digits. And as it turns out, the percentage that we will be getting from HanAll that they're getting from Immunovant is pretty consistent with that. So that's probably as far as I can go in terms of disclosure of that rate. But hopefully that's a little helpful anyway.

Stephen Willey (Analyst)

Nope, that's helpful. Much appreciated, guys. Thank you.

Kurt Gustafson (CFO)

Yeah, thanks, Steve.

Matt Foehr (President and CEO)

Yeah, thanks, Steve.

Operator (participant)

Next question comes from Kripa Devarikonda with Truist Securities. Please go ahead.

Hi, this is Alex Krafka for Kripa. Question from us. We see some of your potential partners rethinking their portfolio, perhaps driven by economic pressures. Are you seeing more or less partners likely to develop molecules in-house and advance to that IND stage? And maybe what are your thoughts on that? And is there any impact or can we see the seed of change that might affect your current business model going forward?

Matt Foehr (President and CEO)

Yeah, thanks, Alex. I'll say a quick answer to your second question. No, we feel great about our business model, about the leverageability in our business and our ability to demonstrate that going forward, and our place in the industry more generally. The partners come to us really for discovery technologies. We don't intend to take programs into IND, that sort of thing. They come to us to get access to our technologies that allow them to get access to broad repertoires of novel antibodies and then to very quickly select winning antibodies that can then be taken forward. So I think we do have a unique vantage point on the industry. Just given that we have intimate relationships with our partners, we understand the sorts of targets they're going after, the ways in which they want to engage targets.

And that informs how we kind of innovate around our early-stage discovery platform. So yeah, I don't see a change in our business model. We feel great about the work that we're doing and our position in the industry. And I think we have a business that's well-positioned for a number of industry cycles. It's designed that way purposefully, and I don't see us really straying from that.

Yeah, that makes a lot of sense. Thanks for the color. And congrats on the progress.

Kurt Gustafson (CFO)

Thank you.

Matt Foehr (President and CEO)

Thank you.

Operator (participant)

Your next question comes from Brendan Smith with TD Cowen. Please go ahead.

Hi, this is Jackie on for Brendan. Just to start off, have you done any beta testing for the OmniHub offering pre-launch? And if so, have you seen any feedback from your customers?

Matt Foehr (President and CEO)

Yeah. Well, Jackie, we obviously interact digitally with our partners all the time. So I guess the short answer to that is yes. And as we've expanded our bioinformatics capabilities over the years and then rolled out our OmniDeep platform over the last couple of years, which is a suite of in silico tools, this really became a real natural extension of the work that we're doing. So short answer is yes, we interact with partners in this way digitally, and we'll be rolling out kind of the brand and more broadly at the AETC conference in December.

Awesome. That's great. And just to follow up on that, are you thinking of partnering with any cloud providers, or are you going to kind of run things on-prem or on your own side of things?

Yeah, at this point, much more homegrown. Obviously, there's a lot of other IT infrastructure behind the scenes, but it's much more homegrown at this point.

Awesome. And then if I could just squeeze one more in. On the three new licenses, could you give us any color on the therapeutic interest or program size expected from these companies and then the mix regarding the platforms they're going to use?

Yeah. So we announced three new deals in the quarter, one with 92Bio, which is a company focused on best-in-class multi-specific antibodies focused solely on cancer. And so they're going to be focused on cancer targets. And then the other two deals were with Memorial Sloan Kettering Cancer Center. Obviously, they have a really deep and long-standing dedication to cancer, a lot of funding into translational research capabilities and a large innovation hub there. They're obviously primarily focused on novel cancer targets. And then the Queen Mary University of London, which, of course, is a top research institute in the UK, they're really focused on cancer prevention as well as diagnostics and theranostics. And those are areas where some of our newer technologies really can be applied well.

So across the board, there's a range of our technologies that these parties will be interested in, much like many of our other partners. And so we're excited to add them on.

Great. Thank you so much. Appreciate it.

Kurt Gustafson (CFO)

Thank you.

Operator (participant)

Your next question comes from Connor McNamara with RBC Capital Markets. Please go ahead.

Conor McNamara (Analyst)

Hey, great. Thanks for taking the question, guys. I got one for each of you. So Matt, just on a product development standpoint, what are you seeing on the development of single-domain antibodies? And what are you seeing on the adoption of OmniChicken with customers?

Matt Foehr (President and CEO)

Yeah. Well, primarily on the single-domain side, obviously, we launched our OmniDab technology about a year ago. And it has been a really significant portion of one of the things that's attracting new partners. And it opens up new possibilities across a range of therapeutic areas. I mentioned growth in the CNS space. That's a big one, as well as radiotherapy. There's a big interest there, and that's attracting a lot of new partners. There's also interest in infectious diseases as well. And that's something that we've had some partnerships in the past, but that has definitely accelerated as well. A lot of different things are driving this. One, the range of routes of administration that single-domain antibodies open the opportunity for, whether that's injectable, inhalable, or oral. The ability to penetrate the blood-brain barrier and have fast or tunable clearance. That's another element that is attracting new partners.

Then an area I'm excited about is just this opening up of new areas, as I said, the diagnostics, the theranostics, radiotherapy. So yeah, it's creating more diversity in our pipeline of programs, which we're excited about.

Conor McNamara (Analyst)

Okay, great. And then, Kurt, just on the ATM, the amount of money you raised, you raised a little over $11 million. And if I just think about that coinciding with kind of a call to push out and what you were expecting from license and milestone revenue, should we be thinking that kind of 11 million is kind of stuff that might have come before the end of 2025, that now maybe you're saying maybe it's going to be pushed out a little bit just because of program timing? Or is there any way to kind of separate how much of that is just safety net versus what you see as potential push out into later than planned revenue from those sources?

Kurt Gustafson (CFO)

Yeah. No, I mean, Connor, I don't think this had to do with sort of filling a specific shortfall that we thought was going to happen in the current quarter or anything like that, or even next quarter. We sort of this was more about as the year progressed, we just were seeing big pharma as well as smaller companies, given sort of changes in the industry and funding cycles and things like that. We got a little bit more cautious just with our outlook and said, "It probably makes some sense to put a little cushion on the balance sheet." So this was the entire amount, I would say, is more in terms of just as we look forward, let's put a little cushion on the balance sheet so that we can make sure we have enough capital to go through various cycles that might occur.

It wasn't, "Hey, we're going to be short $3 million this quarter. Let's go hit the ATM." It was more of a longer-term view.

Conor McNamara (Analyst)

Got it. Thanks for that clarification. And congrats, guys, on the progression of the business.

Kurt Gustafson (CFO)

Yep. No, thanks, Connor.

Operator (participant)

There are no further questions. Please continue.

Matt Foehr (President and CEO)

Great. Thanks. I'd like to thank everyone for joining today's call, and thanks for the questions. We look forward to keeping you updated on our progress and to updating you next quarter. Kurt and I will be at a couple of investor conferences next week. Kurt will be in New York for the Stifel Healthcare Conference, and I'll be in London for the Jefferies Conference, and in the meantime, we appreciate your interest in OmniAb, and thanks again for joining us today.

Operator (participant)

Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.